Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Until 2020, no expert ever saw lockdowns as the appropriate solution - they just didnt happen because they don't stop the endemic spread of a highly infectious virus.
With a few isolated exceptions, covid has spread across the world during multiple lockdowns, so lockdowns clearly haven't worked. They just alter the timeframe a bit (remember "flatten the curve").
I think in time these so-called experts will look back on 2020/21 on what NOT to do.
Given what we've been told about how specific affimers are, I think the 1% is probably a testing glitch and I bet AL is not happy with it. I just hope its not seen as a problem.
Agree that the AN swab method is a huge positive that is taken for granted in the update. But once better publicised, everybody would rather use one of these than a brain tickler.
Avacta actually met their target re AVA6000 target at the year end. Why? Because it was under their control.
The missed targets re the LFT have all been heavily, if not completely dependent on others.
I think we can trust Avacta to deliver, but not AL's misplaced/naive faith in others.
Hi Hank, I didn't mention it because I didn't want to be accused of cross-ramping, but I noticed Hardy_aim and Richard Dutton ramping Portage (PRTG) on twitter, who are nearing phase 2 results for a similar approach to cancer treatment - ie. targeting the tumour.
I've not looked into the detail, (I'm v happy with my Avacta investments), so I don't know how much of a competitive threat it might be, but it served as a reminder not to take for granted other developments.
I would love Avacta to corner the market in this area, but I think we need to be realistic about the possibility of other / similar cancer treatments coming to market in the next year or 2, providing competition.
So, its okay to dream about some of those perfect scenario numbers, but foolish to expect them.
Lots of talk about the price on this board, when all that really matters (for investors) is the development of the science.
If that goes well, the price will look after itself.
I must be missing something - the fundamentals look good, the RNS looked very good (to me), profits increasing, outlook very good . . . . and share price falls!!
I know AIM investments often don't behave logically, so I'm hoping that's why the SP is falling and not that I am actually reading this all wrong.
A recent article I read talked about the pitfalls of emotional decisions based on fluctuating share prices and impatience. It cited a study where the most successful demographic of investors were dead!!
The fundamentals and future potential here are as good as when the SP rocketed.
The problem is, the SP went too high too quick and created unrealistic short term expectations.
Eqtec is a company going in the right direction and should hopefully climb back up again when news flows in - I think investors need some of that patience and fortitude that dead people have in abundance!!
Good luck all.
I read an interesting article this week describing one of the biggest problems for private investors as our own emotions, and over-reacting to share price movements, especially when the SP falls.
Often, buying and holding based on our initial research works best, and it quoted a study of an investment platform where the best performing demographic of investors were . . . . . . Dead!!!
If they deliver on their ambitions - and so far, so good - the growth will be huge.
Mining the minerals and taking them through fully integrated processes to deliver high quality products that are in huge and rapidly increasing demand will be massively profitable.
The strategy looks perfect and they seem in a hurry to achieve it. I’m holding long term here.
GLA.
It happens when an SP is going up or down rapidly and theres a mismatch between buys and sells.
So they stop the market for 5 minutes to try to achieve an average price. If the first one doesnt work, theres a 2nd one where a price will be determined.
So, to investors, it doesnt really mean anything other than a share price is rapidly going up or down.
Well said Sage.
I politely disagreed with ophidian on twitter months ago about tech transfer not being finished, and he just arrogantly, obnoxiously told me how knowledgeable he was and therefore he was correct - and then blocked me! I guess he’s incredibly insecure, as he can’t handle anybody disagreeing with him.
And he was wrong, of course, as he has been wildly wrong on a few of his ‘insights’. But if you predict enough things, eventually you’re going to get something right!
I have no idea whats going on with BAMS, but in my simple mind, I wonder how you can evaluate the degree of test accuracy, when your benchmark - the PCR - is flawed?
Do False positives from the PCR, of which there may be many, get counted as incorrect for BAMS if it correctly doesn’t identify them?
I have no idea how you then check without a fully accurate benchmark?
Could be part of the problem Condor have had, perhaps.
I’ve got a small holding here and am looking to significantly increase it - the potential for the SP to massively increase looks excellent.
But, the director sells in december look significant and a possible red flag. Apologies if this has already been covered, but what are people’s views on the director deals? And am i missing something re the nature of the deals.
I’m still learning, so just looking for some help, thanks.